Life sciences software & AI news

Daily news on AI, software, and digital tools for pharma, biotech, CROs, and life sciences research labs.

Showing 1000+ results
A test tube in a dimly lit lab, symbolizing biopharma research.

May 20, 2026

Cohere Acquires Reliant AI To Expand Into Biopharma And Healthcare

Cohere has announced its acquisition of Reliant AI, a strategic move aimed at enhancing its presence in the biopharma and healthcare sectors. This acquisition integrates Reliant AI’s specialized biomedical datasets and technology into Cohere’s enterprise AI platform, which is tailored for industries with stringent security and compliance requirements.The deal not only strengthens Cohere's foothold in Canada and Germany but also boosts its expansion efforts throughout Europe. By leveraging Relian
A minimalist illustration of a pill representing drug development in biotech.

May 20, 2026

Cohere wants to break into the biotech business

Cohere is making strategic moves to enter the pharmaceutical sector by acquiring Reliant AI, a Montreal-based startup specializing in AI solutions for drug development.This acquisition marks Cohere's second significant move this year, following its merger with Aleph Alpha, a German AI firm. By integrating Reliant's technology into its in-house platform, North, Cohere aims to develop tailored AI tools specifically for biotech companies. Reliant's existing relationships with major pharmaceutical p
A protein sample in a petri dish on a lab bench with a microscope in the background.

May 20, 2026

This AI Biotech Stock Landed a $10.4 Million Nvidia Investment

Nvidia's recent investment in Generate Biomedicines (GENB) highlights the growing intersection of AI and biotechnology. The tech giant acquired 833,325 shares valued at approximately $10.4 million, signaling confidence in the clinical-stage biotech's potential.Generate Biomedicines operates in the innovative field of generative biology, utilizing AI to design new proteins and medicines. This approach aims to expedite the traditionally lengthy drug development process, which often spans years. By
A diagnostic test kit on a lab countertop with laboratory equipment in the background.

May 20, 2026

Revvity Inc. stock (US76155R1086): investors weigh latest earnings and diagnostics focus

Revvity Inc. has updated investors on its recent quarterly financial performance, emphasizing its commitment to diagnostics and life-science tools amidst evolving post-pandemic market dynamics.The company reported its latest earnings, revealing insights into revenue trends and profitability within its diagnostics and life-science portfolio. Despite a normalization following the pandemic peaks, there remains strong demand for core diagnostic testing and scientific instruments. Revvity's focus on
A voice AI device on a lab bench in a dimly lit laboratory

May 20, 2026

Hippocratic AI Expands Life Sciences Leadership Team as Pharma and Medtech Demand for Voice AI Agents Accelerates

Hippocratic AI is enhancing its leadership team to solidify its position as a leader in generative AI for the life sciences sector.Recently, Hippocratic AI announced a series of key executive appointments aimed at expanding its capabilities in the pharmaceutical and medtech industries. This move follows the company's acquisition of Grove AI and the launch of Polaris Life Sciences 5.0, positioning Hippocratic AI as a frontrunner in voice and conversational AI solutions tailored for life sciences
A minimalist illustration of a leaf and a chemical structure in a dark palette.

May 20, 2026

EVGN: Revenue fell sharply and net loss widened as focus shifted to core AI-driven pharma and ag chem

Evogene Ltd. (EVGN) reported a significant decline in revenue and an increased net loss for Q1 2026, primarily due to reduced sales from its Casterra division and rising financing costs.Despite these financial challenges, the company is maintaining its strategic emphasis on developing its AI-driven pharmaceutical and agricultural chemical products. Evogene is actively pursuing new partnerships and advancing its internal research and development efforts to bolster its core pipelines.This shift to
A minimalist illustration of a syringe and vial representing pharmaceutical innovation.

May 20, 2026

Bristol Myers Squibb's Claude deal shows pharma is moving past AI pilots

Bristol Myers Squibb's recent partnership with Anthropic marks a significant shift in how the pharmaceutical industry is integrating AI into its core operations, moving beyond pilot projects to actual implementation.The collaboration aims to embed Anthropic's AI model, Claude, into various functions within Bristol Myers Squibb, including research, clinical development, and manufacturing. This transition indicates a strategic commitment from one of the largest pharmaceutical companies to utilize
A flat silhouette of a regulatory document with a checkmark, symbolizing compliance in life sciences.

May 20, 2026

Ennov Secures Growth Investment From Bregal Sagemount and Ardian to Expand AI-Driven Life Sciences Platform

Ennov has secured a significant growth investment led by Bregal Sagemount, with participation from Ardian, to enhance its AI-driven regulatory and compliance software platform for the life sciences sector.The Paris-based company specializes in software that integrates regulatory, quality, clinical, and pharmacovigilance functions for pharmaceutical and healthcare organizations. The new funding will facilitate advancements in AI product development, support international expansion, and enable bro
Research notes on a desk in an office setting

May 20, 2026

Bristol Myers deepens AI investment with Anthropic deal

Bristol Myers Squibb is enhancing its artificial intelligence capabilities through a collaboration with Anthropic to integrate the AI tool Claude across its operations.The partnership aims to leverage Claude for various functions within the company, including accelerating software and AI development, improving research and manufacturing processes, and enhancing communication with healthcare professionals. Chief Digital and Technology Officer Greg Meyers emphasized the ambition to unlock the valu
Petri dish with cell culture in a laboratory setting

May 20, 2026

My Top 3 Biotech Stocks for May 2026

The current biotech landscape is evolving, with several companies poised for growth amid a more favorable macroeconomic environment. This summary highlights three biotech stocks that show promise for May 2026.Schrödinger, a leader in AI-driven drug discovery, has successfully combined software revenue with its drug development pipeline. The company reported significant revenue growth, with $256 million in total revenue for 2025 and a strong forecast for the upcoming year. Its platform aids major
A minimalist illustration of a DNA strand and molecule in flat design.

May 20, 2026

Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery

Incyte and Genesis Molecular AI have announced a significant expansion of their collaboration aimed at enhancing drug discovery through advanced AI technologies.This partnership marks a pivotal move in the pharmaceutical industry, as it leverages Genesis' GEMS AI platform to utilize Incyte's proprietary experimental data for training large-scale foundation models. The expanded agreement builds on their initial collaboration and aims to accelerate the development of novel molecules across various
A banana peel on a wooden table in a dimly lit lab, with soil samples in the background.

May 20, 2026

Jeff Bezos likens AI boom to the 1990s biotech bubble, says society will benefit anyway

In a recent interview, Jeff Bezos addressed concerns regarding a potential artificial intelligence (AI) bubble, likening the current investment climate to the 1990s biotech boom.Bezos emphasized that despite fears of a bubble, the influx of investment in AI is likely to yield significant benefits for society and technological advancement. He reassured investors and policymakers that even if the current enthusiasm leads to some failures, the overall impact will be positive, as successful innovati